TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...

The Epstein-Barr virus and a high-risk gene may work together to trick the immune system into attacking the brain in MS, a study suggests.

Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...

Sign up for our newsletter to get the latest on the transformative forces shaping the global economy, delivered every Thursday.

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial ...

(Barcelona, Spain, Thursday, 25 September 2025) New research presented today at the 41 st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) reveals ...

Multiple sclerosis (MS) is characterized by a broad array of symptoms. Despite this variability, most individuals with MS will exhibit a distinct set of symptoms during their initial clinical attack.

TG Therapeutics, Inc. announced that it will present data on its multiple sclerosis treatment BRIUMVI® (ublituximab-xiiy) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting in ...

ULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients ...